A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia

A Prospective Open-Label Extension Study (to Study 99784) of Gaboxadol in Primary Insomnia

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00209950

Enrollment

200

Registered

2005-09-21

Start date

2004-07-31

Completion date

2005-09-30

Last updated

2007-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Insomnia

Keywords

Primary insomnia

Brief summary

To evaluate the safety and tolerability of gaboxadol in primary insomnia

Detailed description

To evaluate long-term safety of gaboxadol in healthy adults.

Interventions

DRUGGaboxadol

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* patients with a diagnosis of primary insomnia

Design outcomes

Primary

Measure	Time frame
Safety	—
Tolerability	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026